SAN DIEGO, July 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Thursday, July 12th at 3:00 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:
Media Contact: McDavid Stilwell
Denise PowellVP, Corporate Communications and Business Development
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved